CHICAGO – JUNE 3, 2022 — SimBioSys, the technology company that predicts tumor responses to therapy, announced today it will showcase research at the American Society of Clinical Oncology (ASCO) Annual Meeting 2022 taking place in Chicago from June 3-7.
SimBioSys will present a poster in collaboration with Northwest Community Healthcare on June 6, at 8:00 a.m. CDT during the “Breast Cancer – local/regional/adjuvant” session. In this study, standard of care pre-treatment data collected at the community hospital was used to simulate response to therapy based on the breast cancer patient’s own unique biology. TumorScope showed a high degree of accuracy (over 90 percent) in predicting pathological complete response (pCR) in breast cancer patients.
“We are excited to present this study in collaboration with NCH” said SimBioSys CEO Tushar Pandey. “With this study we show the feasibility of implementing TumorScope in community hospitals and facilitate cancer care as the majority of cancer patients are treated at these institutions.”
Additional research also demonstrates the utility of TumorScope – SimBioSys’ biophysical simulation platform – from capturing spatially resolved single-cell tumor heterogeneity, to predicting response to immunotherapy. The company’s data includes a novel methodology that could provide clarity into a subset of low- and mid-recurrence breast cancer patients that would benefit from chemotherapy and characterization of breast cancer biology in different racial groups.
The full list of SimBioSys abstracts at ASCO 2022, available online here, includes:
- Prediction of Response to Neoadjuvant Therapy (NAT) in Early Breast Cancer (EBC) at Community Hospitals – SimBioSys® TumorScope(TM) Validation Study. In collaboration with Northwest Community Healthcare in Chicago. June 6th, at 8:00 am CDT on the “Breast Cancer – local/regional/adjuvant” session
- The case for simul-omics(TM): identifying IO biomarkers of Ganitumab-Metformin pathological complete response (pCR).
- Novel imaging marker for low- and mid-recurrence score patients at risk for recurrence.
- Multimodal approach to capture spatially resolved single-cell tumor heterogeneity in breast cancer.
- Using a multimodal approach to elucidate racial disparities in breast cancer biology by integrating tumor imaging and -omics data.
For more information on these studies, please visit www.simbiosys.com
About SimBioSys:
SimBioSys is a technology company deploying a combination of artificial intelligence and biophysical simulations to improve our understanding of cancer. By virtualizing cancer, SimBioSys aims to empower clinicians and patients with a better understanding of the disease and the ability to assess all available options computationally to truly individualize treatment.
Media contact:
Andrea Vuturo
Vuturo Group for SimBioSys
andrea@vuturo.com
+1-415-689-8414
